Table 1.
Modification | Residue | Family | Member |
---|---|---|---|
Acetylation | Lysine | BRD | BRD 2/3/4/T/7/9 |
Methylation | Lysine | CRDs | MORF, MRG15 |
Tudor domains | MBT, PHF1/19, TDRD7 | ||
PWWP domains | BRPF1, NSD1-3 | ||
Ankyrin repeats | GLP/G9a | ||
Arginine | Tudor domains | WDR5, TDRD3, SMN1 | |
Phosphorylation | Serine | 14-3-3 proteins BRCT domain | 14-3-3β/γ/η/ε/µ |
Threonine | BIR domain | XRCC1, NBS1, BARD1 | |
Tyrosine | PTB domain | ||
Ubiquitination | Lysine | 53BP1 | |
ADP-ribosylation | Glutamate | Macrodomains | RNF146 |
Arginine | PBZ | APLF, CHFR | |
Glutamate | WWE domain |
BRD, bromodomain; CRD, chromodomain; PWWP, Pro-Trp-Trp-Pro; MORF, monocytic leukemia zinc finger protein-related factor; MRG15, MORF4-related gene on chromosome 15; MBT, malignant brain tumor; PHF, plant homeodomain (PHD) finger; TDRD3/7, Tudor domain containing proteins 3 and 7; BRPF1, BRD and PHD finger-containing protein 1; NSD1-3, nuclear receptor binding SET domain proteins 1-3; GLP, G9a-like protein; WDR5, WD repeat domain 5; SMN1, survival of motor neuron 1; BRCT, BRCA1 C terminus; BIR, baculovirus IAP repeat; XRCC1, X-ray repair cross complementing 1; NBS1, Nijmegen breakage syndrome 1; BARD1, BRCA1 associated RING domain 1; PTB, phosphotyrosine-binding; 53BP1, tumor suppressor p53-binding protein 1; PBZ, PAR-binding zinc finger; WWE, Trp-Trp-Glu; RNF146, RING finger protein 146; APLF, aprataxin and PNKP like factor; CHFR, checkpoint with forkhead and RING finger domains (Adapted from Catia et al., 2019 [26]).